Who is sponsoring MGH-001?

MGH-001 is sponsored by Andrew D. Luster, M.D.,Ph.D..

What condition does MGH-001 study?

MGH-001 studies Asthma, Allergies.

What drugs are being tested in MGH-001?

Interventions: Bronchoscopy, Segmental Allergen Challenge and Broncheoalveolar Lavage, PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging).

What is the status of MGH-001?

MGH-001 is currently COMPLETED.

Last reviewed 2017-09-14 · How we verify

T Cell Effector and Regulatory Mechanisms in Asthma (MGH-001)

NCT01612936 Phase 1 COMPLETED

The specific hypothesis for this study is that there are fundamental differences in T effector and T regulatory cell responses in the lung to allergens in allergic asthma (AA) when compared to allergic nonasthmatics (ANA) that account for the difference in clinical responses. We will address this by comparing T cell responses in AA versus ANA subjects. These experiments will correlate T cell responses with measures of airway physiology using state-of-the art lung imaging and examine mechanisms controlling T cell activation in the airways of AA and the function of airway T regulatory cells during AA.

Details

Lead sponsor	Andrew D. Luster, M.D.,Ph.D.
Phase	Phase 1
Status	COMPLETED
Enrolment	168
Start date	2012-09
Completion	2016-09

Conditions

Asthma
Allergies

Interventions

Bronchoscopy, Segmental Allergen Challenge and Broncheoalveolar Lavage
PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging)

Primary outcomes

Differences in airway physiology and airway constriction — 24 hours
The primary endpoints are differences in airway physiology and airway constriction following segmental allergen challenge (SAC) in AA and ANA subjects using positron emission tomography (PET) in combination with high-resolution computed tomography (HRCT)

Countries

United States